ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 13:42:50 2024-05-23 EDT			5-day change	1st Jan Change
1.04 ^CAD	-0.95%		-3.70%	+15.56%

05-07	ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-23	ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	MT

ZYUS Life Sciences Inc. announced that it has received CAD 20.130131 million in funding from Phoenix Canada Oil Company Limited

June 04, 2023

On June 5, 2023, ZYUS Life Sciences Inc. closed the transaction. The company issued 12,581,332 subscription receipts at an issue price of CAD 1.60 per subscription receipt for gross proceeds of CAD 20,130,131.20.

Latest news about ZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	05-07	CI
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	04-23	MT
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	03-05	MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	02-20	MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	02-20	MT
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	02-01	MT
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	02-01	CI
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	12-05	MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	12-05	CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	11-21	MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	11-21	CI
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023	23-10-24	CI
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board Committees	23-08-31	CI
ZYUS Life Sciences Initiated at Speculative Buy at Stifel GMP; Price Target Set at C$4.00	23-07-07	MT
ZYUS Life Sciences Corporation Strengthens Board of Directors with the Appointment of Wayne Brownlee	23-06-29	CI
ZYUS Life Sciences Corporation Auditor Raises 'Going Concern' Doubt	23-06-28	CI
ZYUS Life Sciences Inc. completed the acquisition of Phoenix Canada Oil Company Limited in a reverse merger transaction.	23-06-08	CI
Phoenix Canada Oil Completes C$20.13-Milion Subscription Receipt Placement Ahead of Reverse Takeover	23-06-06	MT
ZYUS Life Sciences Inc. announced that it has received CAD 20.130131 million in funding from Phoenix Canada Oil Company Limited	23-06-04	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-23	CI
ZYUS Life Sciences Corporation Auditor Raises 'Going Concern' Doubt	23-03-28	CI
ZYUS Life Sciences Corporation announced that it has received $0.018557 million in funding	23-03-01	CI
ZYUS Life Sciences Corporation announced a financing transaction	23-02-15	CI

Chart ZYUS Life Sciences Corporation

Duration

Period

More charts

Company Profile

ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.04 CAD

Average target price

2.75 CAD

Spread / Average Target

+164.42%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ZYUS LIFE SCIENCES CORPORATION	+15.56%	53.78M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+46.06%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research